Novel Modular Vascular Patterning Assay for HTS

HTS 的新型模块化血管模式分析

基本信息

  • 批准号:
    7527007
  • 负责人:
  • 金额:
    $ 28.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The vascular endothelial cells lining blood vessels in humans are one of the principle sites that become involved in inflammatory and proliferative responses to a diverse array of human diseases. Microvascular homeostasis is thus a vital component of human health; its inappropriate activation in response to inflammatory and angiogenic stimuli can become a pathogenic component fueling the growth and spread of cancers, and contributing to debilitating arthritis, age-related macular degeneration and multiple organ failure associated with underlying diseases such as diabetes. On the other hand, impaired angiogenesis is also equally pathogenic, and afflicts its victims by slowing down wound healing and contributing to heart diseases and stroke. Collectively, given the complexity of the angiogenesis signaling system, these major burdens of human health that arise from dysregulation of blood vessel growth need to be addressed by a more concerted effort in drug discovery. Biological assays that model the processes of angiogenic diseases can assist the process of drug discovery and disease target identification. However, currently few assays represent the complexity of the diseased microvasculature as they typically focus on one pathogenic mechanism/pathway. With this in mind, we propose to continue the development of a high content high throughput screening (HC-HTS) vascular patterning assay, which we have recently validated as drug screening tool through a previously funded NIH Roadmap Initiative R21 grant. In this R01 proposal, we plan to extend the scale and scope of the three dimensional endothelial cell sprouting assay (3D-ECSA) to promote its adoption for the HTS paradigm. Our innovative approaches bring in 1) modern automated robotic systems that allow us to improve efficiency and standardize production of spheroids, 2) high content image analysis software to use with 3D-ECSA under HTS conditions, and 3) development of a pilot scale chemical library focused on the immunoproteosome as a chemical enabling tool towards validation of the 3D-ECSA. The successful accomplishments of these goals will not only afford us a valuable tool for large scale biology, but will help bring forward a technology advancement to identify new classes of chemical probes of protein function and drug leads for life saving therapeutics.
描述(由申请人提供):人类血管内衬的血管内皮细胞是参与多种人类疾病的炎症和增殖反应的主要部位之一。因此,微血管稳态是人类健康的重要组成部分;其响应于炎症和血管生成刺激的不适当激活可成为致病组分,促进癌症的生长和扩散,并导致衰弱性关节炎、年龄相关性黄斑变性和与潜在疾病如糖尿病相关的多器官衰竭。另一方面,受损的血管生成也同样具有致病性,并通过减缓伤口愈合和促成心脏病和中风来折磨其受害者。总的来说,考虑到血管生成信号系统的复杂性,这些由血管生长失调引起的人类健康的主要负担需要通过在药物发现方面更加协调一致的努力来解决。模拟血管生成性疾病过程的生物测定可以辅助药物发现和疾病靶点鉴定的过程。然而,目前很少有分析代表患病微血管的复杂性,因为它们通常集中在一种致病机制/途径上。考虑到这一点,我们建议继续开发高含量高通量筛选(HC-HTS)血管图案分析,我们最近通过先前资助的NIH路线图倡议R21赠款验证了该方法作为药物筛选工具。在R 01提案中,我们计划扩展三维内皮细胞发芽试验(3D-ECSA)的规模和范围,以促进其在HTS范例中的采用。我们的创新方法带来了1)现代自动化机器人系统,使我们能够提高效率并标准化球状体的生产,2)在HTS条件下与3D-ECSA一起使用的高内容图像分析软件,以及3)开发中试规模的化学库,重点是免疫蛋白体作为验证3D-ECSA的化学使能工具。这些目标的成功实现不仅为我们提供了大规模生物学的宝贵工具,而且将有助于推动技术进步,以确定蛋白质功能的新化学探针和挽救生命的药物先导物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROYCE MOHAN其他文献

ROYCE MOHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROYCE MOHAN', 18)}}的其他基金

Unraveling the corneal and retinal mechanisms of chemical injury
揭示化学损伤的角膜和视网膜机制
  • 批准号:
    10882069
  • 财政年份:
    2023
  • 资助金额:
    $ 28.96万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10206486
  • 财政年份:
    2021
  • 资助金额:
    $ 28.96万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10459390
  • 财政年份:
    2021
  • 资助金额:
    $ 28.96万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10516386
  • 财政年份:
    2021
  • 资助金额:
    $ 28.96万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10705952
  • 财政年份:
    2021
  • 资助金额:
    $ 28.96万
  • 项目类别:
Defining Corneal Schwann cells in Injury
定义损伤中的角膜雪旺细胞
  • 批准号:
    10308502
  • 财政年份:
    2020
  • 资助金额:
    $ 28.96万
  • 项目类别:
PAD4 in Retinal Gliosis
PAD4 与视网膜神经胶质增生
  • 批准号:
    9436900
  • 财政年份:
    2018
  • 资助金额:
    $ 28.96万
  • 项目类别:
Novel Modular Vascular Patterning Assay for HTS
HTS 的新型模块化血管模式分析
  • 批准号:
    7648164
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:
Novel Modular Vascular Patterning Assay for HTS
HTS 的新型模块化血管模式分析
  • 批准号:
    8243126
  • 财政年份:
    2008
  • 资助金额:
    $ 28.96万
  • 项目类别:
Molecular targets of Corneal Anti-fibrosis
角膜抗纤维化的分子靶点
  • 批准号:
    8589414
  • 财政年份:
    2007
  • 资助金额:
    $ 28.96万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.96万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了